Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.

Abstract

BACKGROUND:

Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap (AAV2-VEGF-Trap) has been reported to inhibit the growth of primary tumor as well as distant metastasis in 4T1 metastatic breast cancer models. The aim of this study was to investigate the inhibiting efficacy of AAV2-VEGF-Trap for glioma.

METHODS:

The intracranial transplanted model of glioma in rats was established. They were treated with AAV2-VEGF-Trap, bevacizumab (BEV), temozolomide (TMZ), TMZ combined with AAV2-VEGF-Trap, TMZ combined with BEV and the control group, respectively. A 7.0 Tesla magnetic resonance (MR) was used to assess the tumor volumes and obtain the apparent diffusion coefficient (ADC) values. Immunohistochemical and terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining were used to evaluate the effects on tumor angiogenesis, proliferation and apoptosis.

RESULTS:

The combination of TMZ with AAV2-VEGF-Trap or BEV showed greater tumor growth inhibition than the other groups, and the ADC values in these two groups were larger than that of the control group. The decreased microvessel density in treatment groups which contain AAV2-VEGF-Trap or BEV was observed. The reduced proliferation activity in groups containing TMZ and increased apoptotic tumor cells in TMZ combined with AAV2-VEGF-Trap group and TMZ combined with BEV group were detected. In addition, there were no differences in antitumor effect, ADC values, Ki-67 and CD31 staining and apoptosis analysis between the two combined therapy groups.

CONCLUSION:

AAV2-VEGF-Trap has an obvious anti-angiogenic effect and inhibits the growth of glioma just by a single intravenous injection, which is similar to BEV. Moreover, there is a synergistic antitumor effect between AAV2-VEGF-Trap and TMZ.

• Authors: Shengnan Zhao, Yakun Zhang, Lei Wang, Li Yang, Liqun Zou, Fabao Gao
• Journal: Cancer biology & therapy (Cancer Biol Ther) Vol. 20 Issue 1 Pg. 65-72 ( 2019) ISSN: 1555-8576 [Electronic] United States
• PMID: 30136881 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Recombinant Fusion Proteins
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• aflibercept
• Bevacizumab
• Receptors, Vascular Endothelial Growth Factor
• Temozolomide

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab (therapeutic use)
• Brain Neoplasms (blood supply, pathology, therapy)
• Cell Line, Tumor (transplantation)
• Combined Modality Therapy (methods)
• Dependovirus
• Disease Models, Animal
• Genetic Therapy (methods)
• Genetic Vectors (administration & dosage, genetics)
• Glioma (blood supply, genetics, pathology, therapy)
• Humans
• Injections, Intravenous
• Male
• Parvovirinae (genetics)
• Rats
• Receptors, Vascular Endothelial Growth Factor (administration & dosage)
• Recombinant Fusion Proteins (administration & dosage)
• Temozolomide (therapeutic use)
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors, genetics, metabolism)